TOLERION, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2001-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.tolerioninc.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
Phase 2
Active, not recruiting
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Tolerion, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03895437
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute UCSD, San Diego, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Mills-Peninsula Medical Center, San Mateo, California, United States
Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)
Phase 2
Withdrawn
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Tolerion, Inc.
- Registration Number
- NCT03794960
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
Phase 2
Withdrawn
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Tolerion, Inc.
- Registration Number
- NCT03794973
- Locations
- 🇺🇸
University of Miami Diabetes Research Institute, Miami, Florida, United States
News
No news found